Non-cystic fibrosis related bronchiectasis is a chronic lung disorder of increasing
importance. This disease is caused by cycles of infection and inflammation in the
lung, resulting in tissue fibrosis, poor gas-exchange, and reduced lung capacity.
Bronchiectasis occurs in about 600,000 people worldwide, with 110,000 of those patients
in the US receive treatments every year1. Exacerbation and hospitalization occurs
about five times per year for each bronchiectatic patient, resulting in >$0.5bn healthcare
burden annually in the US.
Haemophilus influenza, Staphylococcus, P. aeruginosa are major pathogens associated
with disease progression and acute exacerbations in these patients. P. aeruginosa
bateria has been associated with increased disease severity2, which are amenable
to treatment with both AerucinTM and PanaecinTM.
1Bilton et al., Chest 2006; 130:1503–1510. 2 Wilson et al., Eur Respir J 1997; 10:
1754–1760
